Abnormal expression of IGF-binding proteins, an initiating event in idiopathic pulmonary fibrosis?

Pathology Research and Practice

Volumn 206, Issue 8, 2010, Pages 537-543

  Ruan, Wenjing ^a   Ying, Kejing ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Abnormal expression; Idiopathic pulmonary fibrosis; IGFBPs; Pathogenesis

Indexed keywords

BLEOMYCIN; PIRFENIDONE; SIMVASTATIN; SOMATOMEDIN BINDING PROTEIN;

BRONCHIOLE; DISEASE MARKER; DRUG MECHANISM; DRUG TARGETING; EPITHELIUM CELL; EXTRACELLULAR MATRIX; FIBROSING ALVEOLITIS; HUMAN; LUNG ALVEOLUS EPITHELIUM; LUNG FIBROBLAST; LUNG LAVAGE; LUNG PARENCHYMA; MYOFIBROBLAST; NONHUMAN; PATHOGENESIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; RISK FACTOR; ANIMAL; FIBROBLAST; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; FIBROBLASTS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS;

EID: 77954315038     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2010.03.010     Document Type: Review

References (78)

1. American Thoracic Society Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS) and the European Respiratory Society (ERS). Am. J. Respir. Crit. Care Med. 2000, 161:646-664.
2. Gross T.J., Hunninghake G.W. Idiopathic pulmonary fibrosis. N. Engl. J. Med. 2001, 345:517-525.
3. Highland K.B., Silver R.M. New developments in scleroderma interstitial lung disease. Curr. Opin. Rheumatol. 2005, 17:737-745.
4. Crystal R.G., Bitterman P.B., Mossman B., Schwarz M.I., Sheppard D., Almasy L., Chapman H.A., Friedman S.L., King T.E., Leinwand L.A., Liotta L., Martin G.R., Schwartz D.A., Schultz G.S., Wagner C.R., Musson R.A. Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group. Am. J. Respir. Crit. Care Med. 2002, 166:236-246.
5. Reynolds H.Y., Gail D.B., Kiley J.P. Interstitial lung diseases-where we started from and are now going. Sarcoidosis Vasc. Diffuse Lung Dis. 2005, 22:5-12.
6. Friedman S.L. Mechanisms of disease: mechanisms of hepatic fibrosis and therapeutic implications. Nat. Clin. Pract. Gastroenterol. Hepatol. 2004, 1:98-105.
7. Tomasek J.J., Gabbiani G., Hinz B., Chaponnier C., Brown R.A. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat. Rev. Mol. Cell Biol. 2002, 3:349-363.
8. Wynn T.A. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J. Clin. Invest. 2007, 117:524-529.
9. Katzenstein A.L., Myers J.L. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am. J. Respir. Crit. Care Med. 1998, 157:1301-1315.
10. Lelbach A., Muzes G., Feher J. The insulin-like growth factor system: IGFs, IGF-binding proteins and IGFBP-proteases. Acta Physiol. Hung. 2005, 92:97-107.
11. Jones J.I., Clemmons D.R. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 1995, 16:3-34.
12. Baxter R.C., Binoux M.A., Clemmons D.R., Conover C.A., Drop S.L., Holly J.M., Mohan S., Oh Y., Rosenfeld R.G. Recommendations for nomenclature of the insulin-like growth factor binding protein superfamily. Endocrinology 1998, 139:4036.
13. Kim H.S., Nagalla S.R., Oh Y., Wilson E., Roberts C.T., Rosenfeld R.G. Identification of a family of low-affinity insulin-like growth factor binding proteins (IGFBPs): characterization of connective tissue growth factor as a member of the IGFBP superfamily. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:12981-12986.
14. Rosenfeld R.G., Hwa V., Oh Y. Nomenclature of the insulin-like growth factor-binding protein superfamily. J. Clin. Endocrinol. Metab. 2001, 86:946.
15. Hwa V., Oh Y., Rosenfeld R.G. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr. Rev. 1999, 20:761-787.
16. Retsch-Bogart G.Z., Moats-Staats B.M., Howard K., D'Ercole A.J., Stiles A.D. Cellular localization of messenger RNAs for insulin-like growth factors (IGFs), their receptors and binding proteins during fetal rat lung development. Am. J. Respir. Cell Mol. Biol. 1996, 14:61-69.
17. Han R.N., Han V.K., Buch S., Freeman B.A., Post M., Tanswell A.K. Insulin-like growth factor binding proteins in air- and 85% oxygen-exposed adult rat lung. Am. J. Physiol. 1998, 274:L647-L656.
18. Wallen L.D., Myint W., Nygard K., Shimasaki S., Clemmons D.R., Han V.K. Cellular distribution of insulin-like growth factor binding protein mRNAs and peptides during rat lung development. J. Endocrinol. 1997, 155:313-327.
19. Braulke T., Gotz W., Claussen M. Immunohistochemical localization of insulin-like growth factor binding protein-1, -3 and -4 in human fetal tissues and their analysis in media from fetal tissue explants. Growth Regul. 1996, 6:55-65.
20. Chadelat K., Boule M., Corroyer S., Fauroux B., Delaisi B., Tournier G., Clement A. Expression of insulin-like growth factors and their binding proteins by bronchoalveolar cells from children with and without interstitial lung disease. Eur. Respir. J. 1998, 11:1329-1336.
21. Aston C., Jagirdar J., Lee T.C., Hur T., Hintz R.L., Rom W.N. Enhanced insulin-like growth factor molecules in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 1995, 151:1597-1603.
22. Nabeyrat E., Besnard V., Corroyer S., Cazals V., Clement A. Retinoic acid-induced proliferation of lung alveolar epithelial cells: relation with the IGF system. Am. J. Physiol. 1998, 275:L71-L79.
23. Selman M., Pardo A., Barrera L., Estrada A., Watson S.R., Wilson K., Aziz N., Kaminski N., Zlotnik A. Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. Am. J. Respir. Crit. Care Med. 2006, 173:188-198.
24. Camacho-Hubner C., Busby W.H., McCusker R.H., Wright G., Clemmons D.R. Identification of the forms of insulin-like growth factor-binding proteins produced by human fibroblasts and the mechanisms that regulate their secretion. J. Biol. Chem. 1992, 267:11949-11956.
25. Forbes B., Ballard F.J., Wallace J.C. An insulin-like growth factor-binding protein purified from medium conditioned by a human lung fibroblast cell line (He[39]L) has a novel N-terminal sequence. J. Endocrinol. 1990, 126:497-506.
26. Pilewski J.M., Liu L., Henry A.C., Knauer A.V., Feghali-Bostwick C.A. Insulin-like growth factor binding proteins 3 and 5 are overexpressed in idiopathic pulmonary fibrosis and contribute to extracellular matrix deposition. Am. J. Pathol. 2005, 166:399-407.
27. Steffen C.L., Ball-Mirth D.K., Harding P.A., Bhattacharyya N., Pillai S., Brigstock D.R. Characterization of cell-associated and soluble forms of connective tissue growth factor (CTGF) produced by fibroblast cells in vitro. Growth Factors 1998, 15:199-213.
28. Lasky J.A., Ortiz L.A., Tonthat B., Hoyle G.W., Corti M., Athas G., Lungarella G., Brody A., Friedman M. Connective tissue growth factor mRNA expression is upregulated in bleomycin-induced lung fibrosis. Am. J. Physiol. 1998, 275:L365-L371.
29. Cohen P., Rajah R., Rosenbloom J., Herrick D.J. IGFBP-3 mediates TGF-beta1-induced cell growth in human airway smooth muscle cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 2000, 278:L545-L551.
30. Kishibe J., Yamada S., Okada Y., Sato J., Ito A., Miyazaki K., Sugahara K. Structural requirements of heparan sulfate for the binding to the tumor-derived adhesion factor/angiomodulin that induces cord-like structures to ECV-304 human carcinoma cells. J. Biol. Chem. 2000, 275:15321-15329.
31. Girard J.P., Baekkevold E.S., Yamanaka T., Haraldsen G., Brandtzaeg P., Amalric F. Heterogeneity of endothelial cells: the specialized phenotype of human high endothelial venules characterized by suppression subtractive hybridization. Am. J. Pathol. 1999, 155:2043-2055.
32. Izawa D., Tanaka T., Saito K., Ogihara H., Usui T., Kawamoto S., Matsubara K., Okubo K., Miyasaka M. Expression profile of active genes in mouse lymph node high endothelial cells. Int. Immunol. 1999, 11:1989-1998.
33. Boes M., Dake B.L., Booth B.A., Erondu N.E., Oh Y., Hwa V., Rosenfeld R., Bar R.S. Connective tissue growth factor (IGFBP-rP2) expression and regulation in cultured bovine endothelial cells. Endocrinology 1999, 140:1575-1580.
34. Nyman T., Pekonen F. The expression of insulin-like growth factors and their binding proteins in normal human lymphocytes. Acta Endocrinol. (Copenh) 1993, 128:168-172.
35. Pan L.H., Yamauchi K., Uzuki M., Nakanishi T., Takigawa M., Inoue H., Sawai T. Type II alveolar epithelial cells and interstitial fibroblasts express connective tissue growth factor in IPF. Eur. Respir. J. 2001, 17:1220-1227.
36. Allen J.T., Knight R.A., Bloor C.A., Spiteri M.A. Enhanced insulin-like growth factor binding protein-related protein 2 (Connective tissue growth factor) expression in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am. J. Respir. Cell Mol. Biol. 1999, 21:693-700.
37. Snider G.L., Hayes J.A., Korthy A.L. Chronic interstitial pulmonary fibrosis produced in hamsters by endotracheal bleomycin: pathology and stereology. Am. Rev. Respir. Dis. 1978, 117:1099-1108.
38. Kaminski N., Allard J.D., Pittet J.F., Zuo F., Griffiths M.J., Morris D., Huang X., Sheppard D., Heller R.A. Global analysis of gene expression in pulmonary fibrosis reveals distinct programs regulating lung inflammation and fibrosis. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:1778-1783.
39. Zuo F., Kaminski N., Eugui E., Allard J., Yakhini Z., Ben-Dor A., Lollini L., Morris D., Kim Y., DeLustro B., Sheppard D., Pardo A., Selman M., Heller R.A. Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:6292-6297.
40. Pardo A., Selman M. Molecular mechanisms of pulmonary fibrosis. Front. Biosci. 2002, 7:d1743-d1761.
41. Selman M., King T.E., Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann. Intern. Med. 2001, 134:136-151.
42. Eyden B. The myofibroblast: an assessment of controversial issues and a definition useful in diagnosis and research. Ultrastruct. Pathol. 2001, 25:39-50.
43. Willis B.C., Liebler J.M., Luby-Phelps K., Nicholson A.G., Crandall E.D., du Bois R.M., Borok Z. Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. Am. J. Pathol. 2005, 166:1321-1332.
44. Zhang H.Y., Phan S.H. Inhibition of myofibroblast apoptosis by transforming growth factor beta(1). Am. J. Respir. Cell Mol. Biol. 1999, 21:658-665.
45. Kuhn C., McDonald J.A. The roles of the myofibroblast in idiopathic pulmonary fibrosis. Ultrastructural and immunohistochemical features of sites of active extracellular matrix synthesis. Am. J. Pathol. 1991, 138:1257-1265.
46. Leslie K.O., Mitchell J., Low R. Lung myofibroblasts. Cell Motil. Cytoskeleton. 1992, 22:92-98.
47. Moeller A., Gilpin S.E., Ask K., Cox G., Cook D., Gauldie J., Margetts P.J., Farkas L., Dobranowski J., Boylan C., O'Byrne P.M., Strieter R.M., Kolb M. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2009, 179:588-594.
48. Andersson-Sjoland A., de Alba C.G., Nihlberg K., Becerril C., Ramirez R., Pardo A., Westergren-Thorsson G., Selman M. Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis. Int. J. Biochem. Cell Biol. 2008, 40:2129-2140.
49. Grotendorst G.R., Duncan M.R. Individual domains of connective tissue growth factor regulate fibroblast proliferation and myofibroblast differentiation. FASEB J. 2005, 19:729-738.
50. Quan T.E., Cowper S.E., Bucala R. The role of circulating fibrocytes in fibrosis. Curr. Rheumatol. Rep. 2006, 8:145-150.
51. Willis B.C., duBois R.M., Borok Z. Epithelial origin of myofibroblasts during fibrosis in the lung. Proc. Am. Thorac. Soc. 2006, 3:377-382.
52. Zeisberg E.M., Tarnavski O., Zeisberg M., Dorfman A.L., McMullen J.R., Gustafsson E., Chandraker A., Yuan X., Pu W.T., Roberts A.B., Neilson E.G., Sayegh M.H., Izumo S., Kalluri R. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat. Med. 2007, 13:952-961.
53. Yasuoka H., Zhou Z., Pilewski J.M., Oury T.D., Choi A.M., Feghali-Bostwick C.A. Insulin-like growth factor-binding protein-5 induces pulmonary fibrosis and triggers mononuclear cellular infiltration. Am. J. Pathol. 2006, 169:1633-1642.
54. Yasuoka H., Yamaguchi Y., Feghali-Bostwick C.A. The Pro-fibrotic factor IGFBP-5 induces lung fibroblast and mononuclear cell migration. Am. J. Respir. Cell Mol. Biol. 2009, 41:179-188.
55. Abraham D.J., Varga J. Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol. 2005, 26:587-595.
56. Strehlow D., Korn J.H. Biology of the scleroderma fibroblast. Curr. Opin. Rheumatol. 1998, 10:572-578.
57. Varga J., Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J. Clin. Invest. 2007, 117:557-567.
58. Ward P.A., Hunninghake G.W. Lung inflammation and fibrosis. Am. J. Respir. Crit. Care Med. 1998, 157:S123-S129.
59. Grotendorst G.R. Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts. Cytokine Growth Factor Rev. 1997, 8:171-179.
60. Duncan M.R., Frazier K.S., Abramson S., Williams S., Klapper H., Huang X., Grotendorst G.R. Connective tissue growth factor mediates transforming growth factor beta-induced collagen synthesis: down-regulation by cAMP. FASEB J. 1999, 13:1774-1786.
61. Firth S.M., Baxter R.C. Cellular actions of the insulin-like growth factor binding proteins. Endocr. Rev. 2002, 23:824-854.
62. Liu B., Weinzimer S.A., Gibson T.B., Mascarenhas D., Cohen P. Type Ialpha collagen is an IGFBP-3 binding protein. Growth Horm. IGF Res. 2003, 13:89-97.
63. Jones J.I., Gockerman A., Busby W.H., Camacho-Hubner C., Clemmons D.R. Extracellular matrix contains insulin-like growth factor binding protein-5: potentiation of the effects of IGF-I. J. Cell Biol. 1993, 121:679-687.
64. Kireeva M.L., Latinkic B.V., Kolesnikova T.V., Chen C.C., Yang G.P., Abler A.S., Lau L.F. Cyr61 and Fisp12 are both ECM-associated signaling molecules: activities, metabolism, and localization during development. Exp. Cell Res. 1997, 233:63-77.
65. Takehara K. Hypothesis: pathogenesis of systemic sclerosis. J. Rheumatol. 2003, 30:755-759.
66. Lasky J.A., Brody A.R. Interstitial fibrosis and growth factors. Environ. Health Perspect. 2000, 108(Suppl. 4):751-762.
67. Watts K.L., Sampson E.M., Schultz G.S., Spiteri M.A. Simvastatin inhibits growth factor expression and modulates profibrogenic markers in lung fibroblasts. Am. J. Respir. Cell Mol. Biol. 2005, 32:290-300.
68. Watts K.L., Spiteri M.A. Connective tissue growth factor expression and induction by transforming growth factor-beta is abrogated by simvastatin via a Rho signaling mechanism. Am. J. Physiol. Lung Cell. Mol. Physiol. 2004, 287:L1323-L1332.
69. Goppelt-Struebe M., Hahn A., Iwanciw D., Rehm M., Banas B. Regulation of connective tissue growth factor (ccn2; ctgf) gene expression in human mesangial cells: modulation by HMG CoA reductase inhibitors (statins). Mol. Pathol. 2001, 54:176-179.
70. Azuma A., Nukiwa T., Tsuboi E., Suga M., Abe S., Nakata K., Taguchi Y., Nagai S., Itoh H., Ohi M., Sato A., Kudoh S. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2005, 171:1040-1047.
71. Oku H., Shimizu T., Kawabata T., Nagira M., Hikita I., Ueyama A., Matsushima S., Torii M., Arimura A. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur. J. Pharmacol. 2008, 590:400-408.
72. Nakayama S., Mukae H., Sakamoto N., Kakugawa T., Yoshioka S., Soda H., Oku H., Urata Y., Kondo T., Kubota H., Nagata K., Kohno S. Pirfenidone inhibits the expression of HSP47 in TGF-beta1-stimulated human lung fibroblasts. Life Sci. 2008, 82:210-217.
73. Liu H., Drew P., Gaugler A.C., Cheng Y., Visner G.A. Pirfenidone inhibits lung allograft fibrosis through l-arginine-arginase pathway. Am. J. Transplant 2005, 5:1256-1263.
74. Corbel M., Lanchou J., Germain N., Malledant Y., Boichot E., Lagente V. Modulation of airway remodeling-associated mediators by the antifibrotic compound, pirfenidone, and the matrix metalloproteinase inhibitor, batimastat, during acute lung injury in mice. Eur. J. Pharmacol. 2001, 426:113-121.
75. Iyer S.N., Gurujeyalakshmi G., Giri S.N. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J. Pharmacol. Exp. Ther. 1999, 291:367-373.
76. Pen A., Moreno M.J., Durocher Y., Deb-Rinker P., Stanimirovic D.B. Glioblastoma-secreted factors induce IGFBP7 and angiogenesis by modulating Smad-2-dependent TGF-beta signaling. Oncogene 2008, 27:6834-6844.
77. Cohen P., Nunn S.E., Peehl D.M. Transforming growth factor-beta induces growth inhibition and IGF-binding protein-3 production in prostatic stromal cells: abnormalities in cells cultured from benign prostatic hyperplasia tissues. J. Endocrinol. 2000, 164:215-223.
78. Guo Y.S., Townsend C.M., Jin G.F., Beauchamp R.D., Thompson J.C. Differential regulation by TGF-beta 1 and insulin of insulin-like growth factor binding protein-2 in IEC-6 cells. Am. J. Physiol. 1995, 268:E1199-E1204.